(redirected from Bortezomib, Thalidomide and Dexamethasone)
Category filter:
BTDBefore the Dawn
BTDBlood Type Diet
BTDBlack Tie Dinner (various organizations)
BTDBlue Tooth Dongle
BTDBeneficiary Telephone Number Data
BTDButadiene (gas carrier cargo)
BTDBalkan Trust for Democracy (est. 2003; public private partnership)
BTDBilled to Date
BTDBetter Than Dirt (gaming)
BTDBiotinidase (human gene)
BTDBridge to Decision
BTDBoston Transportation Department (Boston, MA, USA)
BTDBridge to the Doctorate (fellowship program)
BTDBearing Temperature Detector
BTDBloons Tower Defense (game)
BTDBanque Togolaise de Développement (French: Togolese Development Bank)
BTDBrightness Temperature Difference
BTDBored To Death
BTDBalloon Tower Defence (gaming)
BTDBuilding Trades Directory (website)
BTDBleed The Dream (band)
BTDBorn to Die
BTDBetter the Devil (record company)
BTDBilateral Trade Database
BTDBurning Trees Daily (clothing company)
BTDBinary To Decimal
BTDBetter Through Design (BTD Manufacturing, Inc.)
BTDBit Transmission Delay
BTDBear Trap Dunes (Ocean View, Delaware, USA)
BTDBest Time of the Day
BTDBrothers Till Death (gaming clan)
BTDBeat The Dow
BTDBorn to Drink
BTDBarney the Dinosaur (TV character)
BTDBiological Therapies in Dentistry (journal)
BTDBrigade Tactical Department (US Military Academy)
BTDBeaulieu-Tan-Damen (pulse shape)
BTDBusiness Travel Department
BTDBrutal Torso Dissection (Australian metal band)
BTDBuy The Dip (stocks)
BTDBusiness Technical Division (USACE)
BTDBeg/Begging to Differ
BTDBattle Training Division (US Army)
BTDBiomechanics Test Database (US National Highway Traffic Safety Administration)
BTDBortezomib, Thalidomide and Dexamethasone (chemotherapy)
BTDBureau Technique de Détection (French plumbing technology company)
BTDBorn to Drive
BTDBlock-Type Decodable
BTDBonneuil Terrassement Démolition (French demolition company)
BTDBasic Thermodynamics
BTDBet the Dealer (gaming)
BTDBig Truck Driver
BTDBeat the Donk Poker Forum
BTDBrown Turtle Designs (Pomona, CA)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
- US-based healthcare company Johnson and Johnson's (NYSE: JNJ) Belgium-based Janssen Pharmaceutical business has received results from the Phase 3 CASSIOPEIA (MMY3006, NCT02541383) study, an Intergroupe Francophone du Myelome study in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Research and Development, LLC., showing that the addition of Darzalex (daratumumab) to bortezomib, thalidomide and dexamethasone before and after autologous stem cell transplantation resulted in higher response rates and longer progression-free survival compared to VTd alone in patients with newly diagnosed multiple myeloma, the company said.
Reportedly, this application seeks to broaden the existing marketing authorisation for daratumumab (DARZALEX) to include use in combination with bortezomib, thalidomide and dexamethasone (VTD) as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant (ASCT).
In the first part of the study, on which the filing is based, participants were randomised to receive either induction (before transplantation) and consolidation (after transplantation) treatment with daratumumab combined with bortezomib, thalidomide and dexamethasone or bortezomib, thalidomide and dexamethasone alone.